{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-036770","form_type":"8-K","ticker":null,"cik":"0001797768","company_name":"Kinnate Biopharma Inc.","filed_at":"2023-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.278437+00:00","generated_at":"2026-06-12T23:14:17.745402+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Kinnate Biopharma amends bylaws on advance notice, universal proxy, and DGCL updates","bullets":["Board approved amended and restated bylaws effective July 25, 2023.","Updates include changes to advance notice procedures for director nominations and stockholder proposals.","Provisions revised to address SEC universal proxy rules and recent DGCL amendments.","Exclusive forum provisions clarified; other ministerial and conforming changes made.","No operational or financial impact; full text of bylaws filed as Exhibit 3.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-036770","json":"https://secwatch.observer/filing/0001140361-23-036770.json","markdown":"https://secwatch.observer/filing/0001140361-23-036770.md","text":"https://secwatch.observer/filing/0001140361-23-036770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1797768/000114036123036770/0001140361-23-036770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1797768/000114036123036770/brhc20056586_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T23:14:17.745402+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a052bf7d46f353954804357e75ab7c88582d9d49","claim":"Kinnate Biopharma Inc.: Amended and restated bylaws to update advance notice procedures, stockholder meeting provisions, director and officer provisions, exclusive forum, and other ministerial changes (effective 2023-07-25).","evidence_excerpt":"On July 25, 2023, the board of directors (the “Board”) of Kinnate Biopharma Inc. (the “Company”) approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), effective immediately, to reflect, among other things:","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797768/000114036123036770/0001140361-23-036770-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-07-25"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}